Stock DRNA DICERNA PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Analyst Reco. Dicerna Pharmaceuticals, Inc.

Equities

DRNA

US2530311081

Analyst Reco.

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Chardan Drops Coverage on Neutral-Rated Dicerna Pharmaceuticals on Acquisition by Novo Nordisk
MT
Chardan Downgrades Dicerna Pharmaceuticals to Neutral Rating From Buy on Proposed Acquisition by Novo Nordisk, Adjusts PT to $38.25 From $28
MT
Chardan Downgrades Dicerna Pharmaceuticals to Neutral From Buy, Adjusts Price Target to $38.25 From $28 on Pending Acquisition
MT
Stifel Downgrades Dicerna Pharmaceuticals to Hold From Buy, Adjusts Price Target to $38 From $35
MT
Alnylam Pharmaceuticals Upgraded to Outperform From Sector Perform by RBC After R&D Day, Price Target Raised to $225 From $144
MT
B. Riley Downgrades Dicerna Pharmaceuticals to Neutral from Buy After Announcing $3.3 Billion Sale to Novo Nordisk, Lifts PT to $38.25 from $35
MT
RBC Downgrades Dicerna Pharmaceuticals to Sector Perform From Outperform, Lifts PT to $38.25 From $30 on Novo Nordisk Deal; Speculative Risk Qualifier Kept
MT
HC Wainwright Downgrades Dicerna Pharmaceuticals to Neutral From Buy, Adjusts PT to $38.35 From $32
MT
DICERNA PHARMACEUTICALS : B. Riley Lowers Dicerna Pharmaceuticals' PT to $35 from $49 on Heels of Revised Corporate Strategy, Keeps Buy Rating
MT
DICERNA PHARMACEUTICALS : Goldman Sachs Cuts Dicerna Pharmaceuticals to Neutral From Buy, Price Target to $25 From $36
MT
DICERNA PHARMACEUTICALS : Chardan Capital Adjusts Price Target on Dicerna Pharmaceuticals to $28 From $34, Maintains Buy Rating
MT
DICERNA PHARMACEUTICALS : HC Wainwright Adjusts Price Target on Dicerna Pharmaceuticals to $32 From $38, Maintains Buy Rating
MT
DICERNA PHARMACEUTICALS : Citigroup Downgrades Dicerna Pharmaceuticals to Neutral From Buy; Price Target is $32
MT
DICERNA PHARMACEUTICALS : SVB Leerink Adjusts Price Target on Dicerna Pharmaceuticals to $47 From $54, Maintains Outperform Rating
MT
DICERNA PHARMACEUTICALS : Goldman Sachs Adjusts Price Target on Dicerna Pharmaceuticals to $36 From $48, Maintains Buy Rating
MT
DICERNA PHARMACEUTICALS : RBC Cuts Price Target on Dicerna Pharmaceuticals to $30 From $35, Reiterates Outperform-Speculative Risk Rating
MT
DICERNA PHARMACEUTICALS : Cowen Downgrades Dicerna Pharmaceuticals to Market Perform From Outperform
MT
DICERNA PHARMACEUTICALS : Truist Securities Downgrades Dicerna Pharmaceuticals to Hold From Buy; Price Target is $32
MT
DICERNA PHARMACEUTICALS : B. Riley Raises Dicerna Pharmaceuticals' PT to $49 from $40 to Reflect Steady Mid-to Late-Stage Pipeline Progression, Keeps Buy Rating
MT
DICERNA PHARMACEUTICALS : HC Wainwright Adjusts Dicerna Pharmaceuticals' Price Target to $42 From $40, Keeps Buy Rating
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. DRNA Stock
  4. News Dicerna Pharmaceuticals, Inc.
  5. Analyst Reco.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW